TMCnet News

Deadline Alert: GPM Reminds Investors of the March 27 Deadline in the Class Action Lawsuit Against PixarBio Corporation
[March 23, 2017]

Deadline Alert: GPM Reminds Investors of the March 27 Deadline in the Class Action Lawsuit Against PixarBio Corporation


Glancy Prongay & Murray LLP ("GPM") reminds investors of the March 27, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased PixarBio Corporation ("PixarBio" or the "Company") (Other OTC: PXRB) securities between October 31, 2016 and January 20, 2017, inclusive (the "Class Period"). PixarBio investors have until March 27, 2017 to file a lead plaintiff motion.

PixarBio is a specialty pharmaceutical/biotechnology company that focuses on the pre-clinical and clinical development of neurological drug delivery systems for pst-operative pain.



On January 3, 2017, PixarBio's Chief Executive Officer, Frank Reynolds, disclosed that the Company had plans to acquire InVivo Therapeutics Holdings Corp. ("InVivo"). In response, InVivo stated that it had never been involved in any negotiations regarding a deal and rejected the offer.

Then on January 23, 2017, citing concerns about possible "manipulative or deceptive activities", the U.S. Securities and Exchange Commission froze trading of PixarBio shares. According to the SEC (News - Alert), "the market for the security appears to reflect manipulative or deceptive activities."


If you purchased or otherwise acquired PixarBio during the Class Period you may move the Court no later than March 27, 2017 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]